Compare WILC & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WILC | PEPG |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 351.4M | 440.0M |
| IPO Year | 2001 | 2022 |
| Metric | WILC | PEPG |
|---|---|---|
| Price | $27.50 | $5.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 2.0K | ★ 692.7K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | ★ 3.06% | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.54 | $0.89 |
| 52 Week High | $31.16 | $7.80 |
| Indicator | WILC | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 45.01 |
| Support Level | $26.52 | $4.36 |
| Resistance Level | $29.11 | $6.81 |
| Average True Range (ATR) | 1.25 | 0.55 |
| MACD | 0.08 | -0.10 |
| Stochastic Oscillator | 52.90 | 26.49 |
G. Willi-Food International Ltd is a company engaged in high-quality, great-tasting kosher food products. The Company is engaged, directly and through subsidiaries, with one segment Import-export, marketing, and distribution of food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Dried Fruit, Nuts and Beans, and Other Products. Its brands include Willi-Food, Euro European Dairies, Donna Rozza, Manchow, Gold Frost, Tifeeret, The Chef Dish, Art Coffe, Mr. Chang, Muchi, Euro Butter, Euro Spread, Euro Cheese, Euro Cream, Euro Dessert, Euro Veg, Ha-Bulgaria, Gelato, and Emma.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.